BrianMShuchMD
Urology • Los Angeles, CAMinimally Invasive Surgery, Surgical Oncology
Associate Professor of Urology, Director of the UCLA Kidney Cancer Program
Dr. Shuch is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
200 UCLA Medical Plz Ste 140
Los Angeles, CA 90095Phone+1 310-206-8164Fax+1 310-206-2369
Summary
- Professor of Urology,
Director of the UCLA Kidney Cancer Program
Education & Training
National Institutes of Health Clinical CenterFellowship, Minimally Invasive Urologic Surgery, 2010 - 2013
UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Urology, 2005 - 2010- UCLA David Geffen School of Medicine/UCLA Medical CenterInternship, Transitional Year, 2004 - 2005
New York University School of MedicineClass of 2004
Certifications & Licensure
CA State Medical License 2006 - 2026
CT State Medical License 2013 - 2019- American Board of Urology Urology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2014
Clinical Trials
- Active Surveillance of the Small Renal Mass Start of enrollment: 2014 Dec 01
- Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy Start of enrollment: 2017 Apr 28
- SPECT/CT for the Characterization of Renal Masses Start of enrollment: 2018 Dec 07
- Join now to see all
Publications & Presentations
PubMed
- Pediatric patients with von Hippel-Lindau and hemangioblastomas treated successfully with belzutifan.Emily Duan, Michael Robinson, Charles Davis, Sumit Pruthi, Christina Shin
Pediatric Blood & Cancer. 2025-01-01 - Final Overall Survival Analysis of S1500: A Randomized, Phase II Study Comparing Sunitinib With Cabozantinib, Crizotinib, and Savolitinib in Advanced Papillary Renal C...Pedro Barata, Catherine Tangen, Melissa Plets, Ian M Thompson Jr, Vivek Narayan
Journal of Clinical Oncology. 2024-11-20 - Impact of postprogression therapies on overall survival: Recommendations from the 2023 kidney cancer association think tank meeting.Stephanie A Berg, Salvatore La Rosa, Tian Zhang, Phillip M Pierorazio, Laurence Albiges
Urologic Oncology. 2024-11-04
Journal Articles
- Krebs-Cycle-Deficient Hereditary Cancer Syndromes Are Defined by Defects in Homologous-Recombination DNA RepairBrian Shuch, Ranjit S Bindra, Christopher D Corso, Peter M Glazer, Nature
Authored Content
- Decisional Regret and Financial Toxicity Among Patients with Benign Renal MassesOctober 2021
Press Mentions
UCLA’s Multidisciplinary Program Transforms the Outlook for People with Von Hippel-Lindau DiseaseNovember 25th, 2024- Novel Imaging Technique Accurate for Detecting Clear-Cell Renal Cell CancerOctober 22nd, 2024
- New Imaging Technique Accurately Detects Aggressive Kidney Cancer, Claims StudyOctober 21st, 2024
- Join now to see all
Committees
- Member, NCI PDQ Kidney Cancer Board
- Kidney Cancer Committee, Society of Urologic Oncology Clinical Trials Consortium
- Co-PI of S1500 Trial, SWOG Genitourinary Cancer Group
Professional Memberships
- Member
- Member
- Society of Urologic Oncology (SUO)Member
External Links
- Faculty Pagehttps://www.uclahealth.org/brian-shuch
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
